| http://purl.uniprot.org/citations/30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/30866857 | http://www.w3.org/2000/01/rdf-schema#comment | "BackgroundPrevious studies have demonstrated that β2-microglobulin (β2M) promotes the growth and survival of a variety of cancer cells and has different regulatory effects on the expression of Bcl-2 and HER2 in HER2- breast cancer cells. However, β2M-mediated signaling in ER+ and ER- breast cancer with HER2- remains unclear.Methodsβ2M expression vector and siRNA were transfected into two types of HER2- breast cancer cells, and the possible relevant signaling molecules were subsequently analyzed by real-time PCR and western blotting. These signaling molecules were also analyzed by real-time PCR and immunohistochemistry (IHC) in two types of HER2- breast cancer tissues, and the associations between β2M and these signaling molecules were assessed using Spearman's correlation analysis.Resultsβ2M silencing downregulated p-SGK1/SGK1 levels and Bcl-2 expression, and β2M overexpression downregulated p-CREB/CREB and significantly upregulated p-SGK1/SGK1 levels and Bcl-2 expression, and both resulting processes did not affect HER2, HIF-1α, VEGF, and ERK signaling in ER+ breast cancer cells with HER2-. β2M silencing upregulated p-CREB/CREB and VEGF protein and significantly downregulated p-ERK/ERK levels, and β2M overexpression downregulated p-CREB/CREB and VEGF, significantly upregulated p-ERK/ERK levels, and both resulting processes did not affect HIF-1α and SGK1 signaling in ER- breast cancer cells with HER2-. β2M expression was positively correlated with p-CREB, p-SGK1, and Bcl-2 expression and had no correlation with HIF-1α, VEGF, and p-ERK1/2, whereas p-SGK1 exhibited a significantly positive correlation with Bcl-2 expression in cancer tissues of patients with luminal A breast cancer, which coincide with the results obtained from the same molecular types of breast cancer cells except CREB signaling. However, β2M expression did not show a significant correlation with HIF-1α, p-CREB, VEGF, p-SGK1, p-ERK1/2, and Bcl-2 expression in cancer tissues of patients with basal-like breast cancer, which was discordant with the results obtained from the same molecular types of breast cancer cells.Conclusionsβ2M has a different molecular regulatory mechanism between ER+ and ER- breast cancer with HER2-, and it may promote tumor survival through the SGK1/Bcl-2 signaling pathway in ER+ breast cancer with HER2- and has no regulatory effects on ER- breast cancer with HER2-."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.org/dc/terms/identifier | "doi:10.1186/s12885-019-5410-1"xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Du H."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Li K."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Yang R."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Xu Y."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Yang S."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Lian X."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/author | "Chai D."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/date | "2019"xsd:gYear |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/name | "BMC Cancer"xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/pages | "223"xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/title | "beta2-microglobulin has a different regulatory molecular mechanism between ERpisup>+pi/sup> and ERpisup>-pi/sup> breast cancer with HER2."xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://purl.uniprot.org/core/volume | "19"xsd:string |
| http://purl.uniprot.org/citations/30866857 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/30866857 |
| http://purl.uniprot.org/citations/30866857 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/30866857 |
| http://purl.uniprot.org/uniprot/#_P61769-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/#_A6XMH4-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/#_A6XMH5-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/#_A6XND9-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/#_B4E0X1-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/#_Q16446-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/#_Q9UM88-mappedCitation-30866857 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/30866857 |
| http://purl.uniprot.org/uniprot/A6XMH4 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/30866857 |